Hemab Therapeutics Holdings, Inc. quarterly report, Q2 FY2026

Business Context and Reporting Period

Hemab Therapeutics Holdings, Inc. (COAG) is a clinical-stage biotechnology company focused on developing therapies for blood coagulation disorders. This Form 10-Q covers the quarterly period ended June 30, 2026. The company completed a corporate reorganization in March 2026 to become a Delaware corporation and successfully closed its Initial Public Offering (IPO) on May 4, 2026. As of June 30, 2026, the company had no products approved for sale and no revenue from product sales.

Key Financial Metrics

Metric Six Months Ended June 30, 2026 Six Months Ended June 30, 2025
Revenue $0 $0
Net Loss $(46.8) million $(27.5) million
Operating Expenses $49.7 million $32.6 million
Research & Development (R&D) $39.8 million $27.0 million
General & Administrative (G&A) $9.9 million $5.6 million
Cash and Cash Equivalents $237.4 million $61.5 million (end of period 2025)
Marketable Securities $220.1 million $97.5 million
Total Liquidity (Cash + Securities) $457.5 million $159.0 million
Accumulated Deficit $(228.7) million $(181.9) million

Material Changes vs. Prior Period

  • Capital Raise: The most significant change was the completion of the IPO in May 2026, raising approximately $317.2 million in net proceeds. This resulted in a substantial increase in cash and marketable securities compared to the prior period.
  • Operating Expenses: Total operating expenses increased by $17.1 million (52%) year-over-year. R&D expenses rose by $12.8 million, driven by increased external costs for product candidates (specifically HMB-003) and higher personnel-related costs. G&A expenses increased by $4.3 million due to higher professional service fees and equity-based compensation.
  • Net Loss: Net loss increased by $19.3 million to $46.8 million, primarily due to the increased operating expenses, partially offset by higher interest income ($4.1 million vs. $0.8 million) resulting from the larger cash balance.
  • Equity Structure: All convertible preferred stock was converted into common stock upon the IPO. The company also implemented a 22-for-1 forward stock split effective April 24, 2026.

Guidance, Outlook, and Risks

Outlook and Liquidity: Management believes that existing cash, cash equivalents, and marketable securities of $457.5 million will fund operating expenses and capital expenditure requirements into 2029. The company expects to continue incurring significant losses as it advances clinical trials.

Clinical Pipeline Updates:

  • Sutacimig: Data from the Phase 1/2 trial in Glanzmann thrombasthenia supported a once-weekly dose of 0.2 mg/kg for the planned Phase 3 trial, which the FDA has endorsed. Initiation of the Phase 3 trial is planned for the second half of 2026.
  • HMB-002: First-in-human data from the VELORA Pioneer Phase 1/2 trial in Von Willebrand Disease showed dose-dependent elevation of VWF and FVIII with a favorable safety profile.
  • HMB-003: Preclinical data demonstrated plasmin inhibition. First-in-human studies are expected to initiate in the second half of 2026.

Risks and Contingencies:

  • Internal Controls: The company identified material weaknesses in its internal control over financial reporting related to the financial statement close process and information system controls. Remediation plans are underway.
  • Thrombosis Risk: Serious adverse events of thrombosis were identified in the development of sutacimig. While a lower dose was selected for Phase 3, the risk of thrombotic events remains a critical safety concern.
  • Regulatory Uncertainty: The FDA may require a randomized controlled trial for sutacimig approval rather than the planned single-arm trial, which could increase costs and delays.
  • Capital Requirements: The company will need substantial additional funding in the future. Failure to raise capital could force delays or elimination of development programs.

Investor Verification Checklist

  • Internal Control Remediation: Verify the progress of remediation plans for the identified material weaknesses in internal controls over financial reporting.
  • Phase 3 Trial Design: Confirm the outcome of the Type D meeting with the FDA regarding the design of the Phase 3 trial for sutacimig (single-arm vs. randomized).
  • Burn Rate: Monitor the quarterly cash burn rate to validate the management's projection of funding sufficiency through 2029.
  • Safety Data: Review upcoming clinical data readouts for sutacimig and HMB-002 for any new safety signals, particularly regarding thrombosis.
  • License Obligations: Review the terms of license agreements with Novo Nordisk and Genmab for potential milestone payments triggered by upcoming regulatory or development events.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.